News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bay Area's InterMune, Inc. (ITMN) Gains As Boehringer Ingelheim Corporation's Rival Drug Shows Mixed Results


3/24/2014 8:19:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim's rival drug had mixed results in late-stage trials. Data from two late-stage trials of Boehringer's nintedanib showed the drug improved patients' lung function, but one trial fell short of meeting its key secondary goals of improving overall health and delaying a disease flare up. Nintedanib and InterMune's pirfenidone are aimed at treating idiopathic pulmonary fibrosis (IPF) — an irreversible condition that leads to progressive loss of lung function due to scarring, which hinders a lung's ability to absorb oxygen.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES